Elizabeth Wilbanks
Family · Corinth, MSNPI 1174870802
Payments from drug & device makers
Across 182 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$522
- AbbVie$307
- Novo Nordisk$297
- Astellas Pharma US Inc$296
- GSK$263
- Pfizer$247
- plus $970 from 25 others
What the payments were for
- Food & beverage$2,902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $522 |
| AbbVie | 21 | $307 |
| Novo Nordisk | 20 | $297 |
| Astellas Pharma US Inc | 14 | $296 |
| GSK | 18 | $263 |
| Pfizer | 19 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 4 | $59 |
| Arbor Pharmaceuticals, Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $54 |
| Corcept Therapeutics | 3 | $49 |
| Dexcom, Inc. | 2 | $46 |
| Abbott | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Bausch Health US, LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Novartis | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$2,902 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $86,131 |
| JardianceEmpagliflozin | 59 | $60,548 |
| RexultiBrexpiprazole | 22 | $34,390 |
| MounjaroTirzepatide | 32 | $32,850 |
| EliquisApixaban | 41 | $31,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $30,860 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $27,621 |
| FarxigaDapagliflozin Propanediol | 32 | $26,263 |
| XareltoRivaroxaban | 17 | $16,712 |
| JanuviaSitagliptin Phosphate | 17 | $13,661 |
| MyrbetriqMirabegron | 24 | $12,528 |
| VascepaIcosapent Ethyl | 18 | $9,337 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $7,729 |
| BrilintaTicagrelor | 13 | $5,385 |
| Colesevelam Hcl | 11 | $2,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $297 | $86,13177 claims |
| Boehringer IngelheimJardiance | $17 | $60,54859 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $91 | $34,39022 claims |
| Lilly USA, LLCMounjaro | $29 | $32,85032 claims |
| PfizerEliquis | $247 | $31,83941 claims |
| AstraZenecaFarxiga, Brilinta | $14 | $31,64745 claims |
| GSKTrelegy Ellipta | $263 | $30,86043 claims |
| Johnson & JohnsonXarelto | $54 | $16,71217 claims |
| MerckJanuvia | $13 | $13,66117 claims |
| Astellas Pharma US IncMyrbetriq | $296 | $12,52824 claims |
| AbbVieSynthroid | $307 | $90718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Corinth
- Phyllis FiveashCorinth$12K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.